New Clinical Trial Information: Ofatumumab + Bendamustine

Trial Information: This is an international Phase III trial of ofatumumab. 338 patients with relapsed or refractory indolent lymphoma, including follicular lymphoma, will be randomized to receive either bendamustine monotherapy or ofatumumab plus bendamustine (O-B), in eight 21-day cycles.

Clinical Trial Information: Ofatumumab in Older Patients

Trial Information: 37 patients over 70 years old are being recruited for a Phase II study of ofatumumab (Arzerra). Patients will be given weekly ofatumumab for eight weeks.

Eligible patients must have indolent lymphoma (follicular lymphoma or marginal zone lymphoma) and be previously untreated.

Clinical Trial Information: Ofatumumab versus Rituximab

Trial Information: This is a Phase III comparative clinical trial of rituximab (Rituxan) and ofatumumab (Arzerra) monotherapy in follicular lymphoma patients who have relapsed following prior therapy with rituximab. 516 patients will be recruited and randomized to rituximab or ofatumumab, in both cases four weekly treatments followed by an additional treatment every two months, for eight months. Patients must have relapsed following a prior chemotherapy regimen that included rituximab.

Research Highlights: Week of December 20, 2010

Beyond my own ramblings, here is an overview of some of the published work that may be of interest to people living with lymphoma, over the past week. I'm skipping over the recent material from ASH, which is of interest in itself. More on that later, perhaps, but there were plenty of interesting papers there, too. Here I look at the December 16 issue of Blood, the December 20 issue of the Journal of Clinical Oncology, December 2010 issues of the British Journal of Cancer, CA, Clinical Lymphoma, Myeloma & Leukemia, Lancet Oncology, and Leukemia & Lymphoma (as dense as always).